Cardiovascular disease and metabolic dysfunction-associated steatotic liver disease: pathophysiology and diagnostic aspects

被引:1
|
作者
Moller, Soren [1 ,2 ]
Kimer, Nina [3 ]
Hove, Jens Dahlgaard [2 ,4 ]
Barlose, Mads [1 ]
Gluud, Lise Lotte [2 ,3 ]
机构
[1] Copenhagen Univ Hosp Hvidovre, Ctr Funct & Diagnost Imaging & Res, Dept Clin Physiol & Nucl Med, Kettegard Alle 30, DK-2650 Hvidovre, Denmark
[2] Univ Copenhagen, Fac Hlth Sci, Dept Clin Med, Blegdamsvej 3, DK-2200 Copenhagen, Denmark
[3] Copenhagen Univ Hosp Hvidovre, Med Div, Gastro Unit, DK-2650 Hvidovre, Denmark
[4] Copenhagen Univ Hosp Hvidovre, Dept Cardiol, DK-2650 Hvidovre, Denmark
关键词
Chronic liver disease; Non-alcoholic fatty liver disease; Cirrhosis; Atherosclerosis; Coronary artery disease; Diabetes; Obesity; NONALCOHOLIC FATTY LIVER; ANGIOTENSIN-ALDOSTERONE SYSTEM; PORTAL-HYPERTENSION; FIBROSIS STAGE; HEART-FAILURE; RISK; ATHEROSCLEROSIS; STEATOHEPATITIS; MORTALITY; STATEMENT;
D O I
10.1093/eurjpc/zwae306
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Metabolic dysfunction-associated steatotic liver disease (MASLD) can be interpreted as the hepatic expression of metabolic syndrome, which is estimated to affect 30% of the adult population. Obesity, dyslipidaemia, arterial hypertension, and T2DM are considered significant risk factors of MASLD. The relationship is two-way with MASLD found in up to 75% of patients with T2DM. Importantly, MASLD is associated with increased risk of cardiovascular diseases (CVD) such as arrhythmia, atherosclerotic heart disease, heart failure, and CVD-associated mortality. In addition, MASLD patients present with a high prevalence of major adverse cardiac events, which calls for systematic surveillance of CVD in MASLD. This review focuses on the pathophysiology behind development of CVD in MASLD, the types of cardiovascular complications, morbidity and survival, and suggestions for evaluation of patients with MASLD.
引用
收藏
页数:13
相关论文
共 50 条
  • [1] Metabolic dysfunction-associated steatotic liver disease and atherosclerosis
    Castillo-Nunez, Yulino
    Almeda-Valdes, Paloma
    Gonzalez-Galvez, Guillermo
    Arechavaleta-Granell, Maria del Rosario
    CURRENT DIABETES REPORTS, 2024, 24 (07) : 158 - 166
  • [2] Cardiovascular Risk Reduction in Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis
    Bernhard, Johannes
    Galli, Lukas
    Speidl, Walter S.
    Krychtiuk, Konstantin A.
    CURRENT CARDIOLOGY REPORTS, 2025, 27 (01)
  • [3] Evolutionary aspects of metabolic dysfunction-associated steatotic liver disease (MASLD)
    Geier, Andreas
    Schiffels, Stephan
    Krawczyk, Marcin
    GASTROENTEROLOGIE, 2025,
  • [4] Natural history of metabolic dysfunction-associated steatotic liver disease
    Lekakis, Vasileios
    Papatheodoridis, George, V
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2024, 122 : 3 - 10
  • [5] Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis: The Patient and Physician Perspective
    Eskridge, Wayne
    Cryer, Donna R.
    Schattenberg, Joern M.
    Gastaldelli, Amalia
    Malhi, Harmeet
    Allen, Alina M.
    Noureddin, Mazen
    Sanyal, Arun J.
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (19)
  • [6] Metabolic Dysfunction-Associated Steatotic Liver Disease
    Ali, Sajjadh M. J.
    Lai, Michelle
    ANNALS OF INTERNAL MEDICINE, 2025, 178 (01) : ITC1 - ITC17
  • [7] Cardiovascular disease in patients with metabolic dysfunction-associated steatohepatitis compared with metabolic dysfunction-associated steatotic liver disease and other liver diseases: A systematic review
    Sanyal, Arun J.
    Husain, Mansoor
    Diab, Crystel
    Mangla, Kamal Kant
    Shoeb, Ahsan
    Lingvay, Ildiko
    Tapper, Elliot B.
    AMERICAN HEART JOURNAL PLUS: CARDIOLOGY RESEARCH AND PRACTICE, 2024, 41
  • [8] Monitoring disease progression in metabolic dysfunction-associated steatotic liver disease
    Noureddin, Nabil
    Copur-Dahi, Nedret
    Loomba, Rohit
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2024, 59 : S41 - S51
  • [9] The association between metabolic dysfunction-associated steatotic liver disease, cardiovascular and cerebrovascular diseases and the thickness of carotid plaque
    Huang, Yunqian
    Wang, Yuqun
    Xiao, Zhengguang
    Yao, Shengqi
    Tang, Yuhua
    Zhou, Linjun
    Wang, Qin
    Xie, Yanchun
    Zhang, Lixia
    Zhou, Yan
    Lu, Ying
    Zhu, Wenqian
    Chen, Man
    BMC CARDIOVASCULAR DISORDERS, 2023, 23 (01)
  • [10] Retinopathy in Metabolic Dysfunction-Associated Steatotic Liver Disease
    Orfanidou, Myrsini
    Polyzos, Stergios A.
    MEDICINA-LITHUANIA, 2025, 61 (01):